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The health and financial impact of the obesity epidemic has become a worldwide challenge in the past decades. Despite widespread pub-
lic health policies and efforts to combat the grow-
ing rate of obesity, over 2 billion people are obese or 
overweight.(1) Excessive weight is associated with an 
increased incidence of cardiovascular disease, hyper-
tension, stroke, type 2 diabetes mellitus and malig-
nancy, and obesity-associated insulin resistance is 
central to metabolic disturbances.(2) Nonalcoholic 
fatty liver disease (NAFLD), of which the spectrum 
ranges from simple steatosis to nonalcoholic steato-
hepatitis (NASH), is a prominent obesity-associated 
comorbidity.
Although dyslipidemia is a hallmark of NAFLD, 
the mechanisms through which aberrant lipogenesis 
contributes to NAFLD are not fully understood.(3) 
Both genetic and environmental factors are associated 
with NAFLD development. Genetic factors include 
specific genotypes (PNPLA3, TM6SF2, and GCKR), 
which have been found to predict NASH and severe 
liver disease, but have no significant connection to 
type 2 diabetes.(4,5) Environmental factors include 
high caloric intake, which leads to hepatic lipid over-
flow.(6) Insulin resistance holds the critical mechanistic 
function of impairing insulin action, resulting in up- 
regulation of hepatic de novo lipogenesis and triglycer-
ide (TG) synthesis, and increased fatty acid delivery 
to the liver.(6) Regardless of phenotype, a critical 
histological and metabolic feature of NAFLD is the 
accumulation of TG in the liver, which when in excess 
can lead to hepatic steatosis, which may further pro-
mote cell death, inflammation, and hepatic stellate cell 
activation, developing NASH and fibrosis.(3,7) More 
recent literature has implicated carboxylesterases in 
NAFLD and obesity. Specific roles include regula-
tion of both TG pools for very low density lipopro-
tein synthesis, the size and number of cytosolic lipid 
droplets, as well as the impact on blood fatty acid con-
centration and insulin sensitivity.(8) Two recent studies 
demonstrated reductions in hepatic carboxylesterase 2 
(CES2) levels in the development of NAFLD in mice 
and in human obesity.(9,10) Notably, in diabetic and 
high-fat diet (HFD) fed mice, restoration of hepatic 
CES2 expression reversed liver steatosis and insulin 
resistance.(10)
Although previous studies had provided evidence 
of the role of hepatic carboxylesterase 2c (Ces2c) 
in the development of NAFLD, Ces2c is highly 
expressed in the intestine. Therefore, in this issue of 
Hepatology Communications,(11) Maresch et al. 
have further demonstrated the impact of intestinal 
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Ces2c activity in NAFLD development and hepatic 
insulin sensitivity. The authors initially assessed the 
role of Ces2c and its proposed human orthologue 
CES2 through transient overexpression in COS-7 
cells. Overexpressed Ces2c or CES2 increased neu-
tral TG hydrolysis and diglyceride (DG) hydrolysis 
activities. Furthermore, Ces2c overexpression led to 
an increase fatty acid oxidation, suggesting that fatty 
acids are generated by lipid hydrolysis for further 
degradation.
To study the specific role of Ces2c in the intestine, 
the authors generated new intestine-specific Ces2c 
transgenic mice. These mice showed increased TG 
hydrolysis and fatty acid oxidation in the small intes-
tine. In parallel, fatty acid oxidation–regulating genes, 
including PPARα and CPT1a, were up-regulated.
To address their central question of whether intes-
tinal lipid metabolism regulated by Ces2c affects liver 
pathophysiology, the study further investigated the 
role of Ces2c activity in the development of HFD-
induced weight gain, NAFLD, and insulin resistance. 
When mice were fed HFD, wild-type (WT) mice 
showed increased body weight, but the body weight 
of Ces2c transgenic mice was significantly low com-
pared with WT controls. Interestingly, activity levels 
and daily/total food intake were comparable between 
both groups. Importantly, intestinal Ces2c transgenic 
mice displayed reduced hepatic TG content and his-
tological steatosis, which is normally increased in WT 
mice when fed with HFD. In addition to reduced his-
tological evidence of hepatic steatosis, inflammatory 
and fibrotic markers were also decreased in intestinal 
Ces2c transgenic mice.
In addition, the study evaluated systemic insu-
lin resistance, which could be associated with the 
severity of NAFLD. In Ces2c transgenic mice, glu-
cose clearance and insulin sensitivity were improved. 
Importantly, in intestinal Ces2c transgenic mice there 
was an increase in phosphorylation of protein kinase 
B (Akt), a downstream kinase of insulin signaling, 
suggesting improved hepatic insulin sensitivity. The 
authors commented on how intestinal Ces2c overex-
pression did not affect Akt phosphorylation in skeletal 
muscle, suggesting that the role that insulin signal-
ing played in skeletal muscle is not strong. Therefore, 
the study suggested that intestinal Ces2c overexpres-
sion improved hepatic insulin signaling, rather than 
systemic insulin resistance. However, drawing this 
conclusion might require further investigation, as Akt 
is not only activated by insulin.
Finally, the question remains as to how increased 
intestinal Ces2c expression affects the observed 
hepatic phenotype and provides protection from 
HFD-induced insulin resistance in this study. Dietary 
fat absorption in intestinal Ces2cint mice was vir-
tually identical to control mice, and no significant 
changes were observed in overall energy expenditure. 
Furthermore, the authors provide data demonstrating 
similar rates of lipid entry/secretion into the circula-
tion in transgenic mice when compared with controls. 
This, together with the normal food intake previously 
mentioned in transgenic and control mice, suggest 
other mechanisms at play. Finally, the authors go on 
to assess postprandial lipidemia. Notably, enhanced 
chylomicron TG clearance and apolipoprotein B48 
levels were observed after fat challenge orally in intes-
tinal Ces2c transgenic mice. In parallel with previ-
ous data suggesting that increased chylomicron size 
enhances TG clearance, final experiments in this 
study demonstrated that isolated chylomicrons were 
larger in size and diameter. The authors go on to 
note increased postprandial TG clearance in intestinal 
Ces2c transgenic mice as the possible mechanism that 
lowers lipid flux and lipid accumulation in the liver, 
leading to protective effects from obesity-induced 
NAFLD. Given that messenger RNA expression of 
genes involved in fatty acid oxidation was increased in 
skeletal muscles, the authors speculate lipid mobiliza-
tion into skeletal muscle as the site of lipid clearance. 
However, this requires further investigation as the evi-
dence is not fully clear.
This study proposed at least two major mechanisms 
of the potential of intestinal Ces2c on lipid metabolism. 
One is that intestinal Ces2c overexpression increases 
the hydrolysis of TG and DG, which generates fatty 
acids for degradation through fatty acid oxidation. The 
other is that DG and monoglyceride generation from 
the hydrolysis of lipids, of which the re-esterification is 
enhanced, increases the apolipoprotein B48–containing 
particle size, further promoting enhanced chylomicron 
clearance from the circulation. Thus, enhanced intesti-
nal Ces2c activity could mitigate NAFLD and insulin 
resistance by reducing hepatic, intestinal, and systemic 
lipid content through degrading and eliminating the 
lipids from the body. The most important argument 
of this study is that modulation of intestinal lipid 
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metabolism by enhancing intestinal Ces2c expression 
has the potential to affect hepatic and systemic lipid 
metabolism, regulating the development of NAFLD 
and systemic insulin resistance. This further suggests 
that medications to increase intestinal CES2 activ-
ity can be a future effective therapy for NAFLD and 
diabetes.
Although this study has illustrated the important 
role of intestinal lipid metabolism, several questions 
remain to be answered. Given the difference between 
known carboxylase 2 family members in mice and 
humans, further studies are needed to investigate the 
biological similarities and cross activities against the 
proposed human carboxylase orthologue, CES2. As 
recent studies demonstrated a link between reduced 
hepatic expression of Ces2c and CES2 in NAFLD 
development in obese mice and humans, respectively, 
it would prove useful to similarly characterize the 
expression in intestinal samples of obese humans and 
mice. Additionally, work must be done to further dif-
ferentiate the advantages of targeting intestinal lipid 
carboxylase activity versus hepatic. Nonetheless, this 
study provides evidence highlighting the importance 
of intestinal lipid homeostasis in obesity and devel-
opment of weight-associated comorbidities such as 
NAFLD.
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